ARGOS THERAPEUTICS AND NOVO NORDISK ANNOUNCE AGREEMENT TO DEVELOP TREATMENT FOR SYSTEMIC AUTOIMMUNE DISORDERS
Immunotherapy pioneer Argos Therapeutics and
global healthcare leader Novo Nordisk, announced they have entered into an agreement
under which Argos has licensed to Novo Nordisk antibody technology for research
and development of a treatment for systemic immune disorders, including systemic
lupus erythematosus (SLE).